In November 2021, under the auspices of WHO’s COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool signed a worldwide licence with the Spanish National Research Council (CSIC) for a COVID-19 serological antibody diagnostic test. The diagnostic test effectively checks for the presence of anti-SARS-CoV-2 antibodies developed either in response to a COVID-19 infection or to a vaccine.

MPP invites interested manufacturers based anywhere in the world to express their interest in obtaining a sublicence by submitting a single email to with complete, detailed responses to the questionnaire provided here.

Key Features
Technology Patents, biological material necessary for manufacture of the diagnostic test
Know-how CSIC to provide all necessary know-how to MPP and/or licensees
Field of use ELISA kits and lateral flow test for the detection of antibodies against COVID-19
Territory Worldwide
Scope of the grant Non-exclusive right to grant sublicences to develop the licensed patents/know-how/material into licensed products, and to commercialise licensed products
Royalties Royalty-free for LMICs; 15% for HICs where there is a Patent granted and in force, or where no Patent if Licensee has used the Material
Country List